Keytruda (pembrolizumab)

pCPA File Number: 21036
Negotiation Status:
Concluded with an LOI
Indication(s):
Metastatic Urothelial Carcinoma
Sponsor/Manufacturer:
Merck Canada
CDA-AMC Project Number:
pCODR 10117
pCPA Engagement Letter Issued:
Negotiation Process Concluded: